Cargando…

Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis

BACKGROUND & AIMS: Treatment rates with interferon-based therapies for chronic hepatitis C have been low. Our aim was to perform a systematic review of available data to estimate the rates and barriers for antiviral therapy for chronic hepatitis C. METHODS: We conducted a systematic review and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vutien, Philip, Jin, Michelle, Le, Michael H., Nguyen, Pauline, Trinh, Sam, Huang, Jee-Fu, Yu, Ming-Lung, Chuang, Wan-Long, Nguyen, Mindie H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587234/ https://www.ncbi.nlm.nih.gov/pubmed/28877190 http://dx.doi.org/10.1371/journal.pone.0183851

Ejemplares similares

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States
por: Vutien, Philip, et al.
Publicado: (2016)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors
por: Wong, Alina, et al.
Publicado: (2018)

Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B
por: Wang, Christina, et al.
Publicado: (2016)

Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma
por: Estevez, Jacqueline, et al.
Publicado: (2017)

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care
por: Vu, Vinh D, et al.
Publicado: (2015)

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection
por: Jun, Tomi, et al.
Publicado: (2019)

Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis
por: Park, Haesuk, et al.
Publicado: (2018)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

Correction: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis
por: Park, Haesuk, et al.
Publicado: (2018)

Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States
por: Nguyen, Vy H., et al.
Publicado: (2022)

Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers
por: Chen, Vincent L., et al.
Publicado: (2017)

Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California
por: Toy, Mehlika, et al.
Publicado: (2018)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

Host factors determining the efficacy of hepatitis C treatment
por: Chuang, Wan-Long, et al.
Publicado: (2012)

Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar
por: Kim, Yoona A., et al.
Publicado: (2017)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
por: Hoang, Joseph K., et al.
Publicado: (2016)

Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis
por: Lee, Hyo-Young, et al.
Publicado: (2019)

Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B
por: Huang, Daniel Q., et al.
Publicado: (2023)

Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000–2015
por: Liu, Anne, et al.
Publicado: (2018)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016
por: Le, Michael H., et al.
Publicado: (2020)

The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan
por: Joseph, Keva, et al.
Publicado: (2021)

Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
por: Ito, Takanori, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease and non-liver comorbidities
por: Manikat, Richie, et al.
Publicado: (2023)

Transient Elastography and Serum-Based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort: A Cross-Sectional Analysis
por: Le, Michael H., et al.
Publicado: (2022)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam
por: Le, Van Quang, et al.
Publicado: (2019)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic
por: Toyoda, Hidenori, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross‐Sectional Population‐Based Study on Its Relationship From 1999 to 2016
por: Le, Michael H., et al.
Publicado: (2019)

Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits
por: Emhmed Ali, Saad, et al.
Publicado: (2021)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR
por: Yeh, Ming-Lun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_62ng8s4j7ol1h7uuemfsovmfef